当前位置:
X-MOL 学术
›
Anti-Cancer Drugs
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Anti-Cancer Drugs ( IF 1.8 ) Pub Date : 2021-09-13 , DOI: 10.1097/cad.0000000000001219 Peter G Rose 1, 2 , Meng Yao 3 , Laura M Chambers 1, 2 , Haider Mahdi 1, 2 , Robert DeBernardo 1, 2 , Chad M Michener 1, 2 , Miriam AlHilli 1, 2 , Stephanie Ricci 1, 2 , Roberto Vargas 1, 2
Anti-Cancer Drugs ( IF 1.8 ) Pub Date : 2021-09-13 , DOI: 10.1097/cad.0000000000001219 Peter G Rose 1, 2 , Meng Yao 3 , Laura M Chambers 1, 2 , Haider Mahdi 1, 2 , Robert DeBernardo 1, 2 , Chad M Michener 1, 2 , Miriam AlHilli 1, 2 , Stephanie Ricci 1, 2 , Roberto Vargas 1, 2
Affiliation
To determine the effect of poly-adenosine ribose phosphatase inhibitors (PARPi) on the response to subsequent platinum-based chemotherapy (PBC) in patients with recurrent, platinum-sensitive BRCA-mutated epithelial ovarian, peritoneal, or fallopian cancer (BRCAm EOC).
中文翻译:
PARP 抑制剂降低了 BRCA 突变卵巢癌患者对后续铂类化疗的反应。
确定聚腺苷核糖磷酸酶抑制剂 (PARPi) 对复发性、铂敏感 BRCA 突变的上皮性卵巢癌、腹膜癌或输卵管癌 (BRCAm EOC) 患者对后续铂类化疗 (PBC) 反应的影响。
更新日期:2021-09-13
中文翻译:
PARP 抑制剂降低了 BRCA 突变卵巢癌患者对后续铂类化疗的反应。
确定聚腺苷核糖磷酸酶抑制剂 (PARPi) 对复发性、铂敏感 BRCA 突变的上皮性卵巢癌、腹膜癌或输卵管癌 (BRCAm EOC) 患者对后续铂类化疗 (PBC) 反应的影响。